Reversible adult respiratory distress in primary antiphospholipid syndrome

• Published in: Haematologica (Roma) Vol. 85; no. 2; pp. 208 - 210
• Main Authors: Camera, A, Rocco, S, De Lucia, D, Silvia, C, Lucania, A, Servillo, G, Valentini, G, Rotoli, B
• Format: Journal Article
• Language: English
• Published: Pavia Haematologica 01.02.2000
• Subjects: Adolescent; Antiphospholipid Syndrome; Biological and medical sciences; General aspects; Glucocorticoids - administration & dosage; Glucocorticoids - therapeutic use; Humans; Immunopathology; Infant, Newborn; Male; Medical sciences; Methylprednisolone - administration & dosage; Methylprednisolone - therapeutic use; Respiratory Distress Syndrome, Newborn - drug therapy; Respiratory Distress Syndrome, Newborn - etiology; Respiratory Distress Syndrome, Newborn - physiopathology; Human; Immunopathology; Corticosteroid; Antiphospholipid antibody syndrome; Intravenous administration; Cardiovascular disease; Autoimmune disease; Male; Hemopathy; Methylprednisolone; Glucocorticoid; Vascular disease; Case study; Chemotherapy; Platelet; Treatment; Adult respiratory distress syndrome; Adolescent; Complication; High dose
• ISSN: 0390-6078; 1592-8721

Division of Hematology OFederico IIO University, Naples, Italy. Antiphospholipid antibody syndrome (APS) is a disorder caused by circulating antibodies reacting with biological membranes and characterized by recurrent thrombosis, chronic thrombocytopenia and miscarriages. It has been reported to occur either as a primary syndrome or secondary to systemic autoimmune disorders. We describe a case of primary APS in a young patient, in whom the clinical course was particularly severe and complicated by a respiratory distress syndrome. The patient was resistant to a number of treatments, and eventually responded to intravenous high dose corticosteroids.